Harnessing the microbiome to treat skin disease

cubes-home

Our Approach

Leveraging skin microbiome to discover and develop novel products for skin conditions and diseases

Azitra Inc. is an emerging biotechnology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases. The Company’s technology platform offers multiple product opportunities in three areas: (1) consumer health products based on microbial strains and their components; (2) pharmaceuticals based on the delivery of biotherapeutic proteins to the skin via proprietary bacteria strains; and (3) discovery and development of novel bioactive compounds — e.g., antimicrobials and other therapeutics based on the metabolic products of commensal skin bacteria. Azitra’s lead programs are focused on eczema (atopic dermatitis) and ichthyosis vulgaris, inflammatory skin conditions, dry or irritated skin, and orphan skin diseases including Netherton syndrome.

Driven Leadership

Our Leadership Team

Richard Andrews
pipebar

Richard Andrews, SM, MS

President and CEO

pipebar

Travis Whitfill, MPH

Co-Founder and CSO

pipebar

Gilles Dube, PhD

Sr. Director Product Development

pipebar

Roger Leger, PhD

Sr. Director Formulation & Product Systems

pipebar

David Dodds, PhD

Chief Technical Officer

Board of Directors

Richard Andrews
pipebar

Richard Andrews, SM, MS

President and CEO

pipebar

Travis Whitfill, MPH

Co-Founder and CSO

pipebar

Azim Munivar, MD

Co-Founder, Resident Physician, Yale University School of Medicine

pipebar

Stella M. Roberston, PhD

Partner, Bios Partners

pipebar

Daniel Wagner

Managing Director, Investments Connecticut Innovations

Investors

Additional Support

Top